Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab in Behcet's Syndrome
NCT01693653Phase 2Terminated
- Sponsor
- NYU Langone Health
- Start
- Sep 2012
- Primary completion
- Nov 2013
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of tocilizumab in Behçet's syndrome (BD), sponsored by NYU Langone Health. Started Sep 2012; status: terminated.
02
Drugs
tocilizumab
03
Conditions
Behçet's syndrome (BD)
Beyond the preview
Go deeper on NCT01693653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01693653.